MetCure Therapeutics LLC — Department of Health and Human Services STTR Phase I: 102
MetCure Therapeutics LLC — STTR Phase I award from Department of Health and Human Services.
- Amount
- $224,999
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- STTR · Phase I
- Topic
- 102
- Solicitation
- PA15-270
- NAICS
- —
- Place of performance
- GA
- Period
- 2016-09-15 → 2018-08-31
Description
Enzalutamide resistance is a major obstacle in the treatment of metastatic castration resistant prostate cancer mCRPC Recently we developed a small molecule lead compound BKM and demonstrated its potent activity against bone metastatic prostate cancer cells In this Phase I STTR application we hypothesize that BKM is a novel targeted therapy to overcome enzalutamide resistance and effectively target bone metastasis Two Aims are proposed Aim will evaluate the in vivo pharmacokinetics distribution and efficacy of BKM in targeting enzalutamide resistant bone metastatic prostate cancer in animal models Aim will determine the mechanism of action of BKM in mCRPC cells The project has immediate therapeutic potential in treating a lethal disease In this Phase I STTR application we will develop a small molecule drug BKM to overcome enzalutamide resistance and treat bone metastatic prostate cancer a major cause of cancer death in American men This project has immediate potential in treating a lethal disease reducing cancer morbidity and improving healthcare in the United States and globally